Economic burden of hemophilia A and B: a case in Iran

References

• Buckley B, Dreyfus J, Prasad M, et al. Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals. Haemophilia. 2018;24(3):e93–e102. doi: 10.1111/hae.13404
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer A, Mauser Bunschoten E, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47. doi: 10.1111/j.1365-2516.2012.02909.x
   PubMed Web of Science ®Google Scholar
• O’Hara J, Walsh S, Camp C, et al. The relationship between target joints and direct resource use in severe haemophilia. Health Econ Rew. 2018;8(1):1–7. doi: 10.1186/s13561-018-0185-7
   PubMedGoogle Scholar
• Zhou Z-Y, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457–465. doi: 10.3111/13696998.2015.1016228
   PubMed Web of Science ®Google Scholar
• Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Health. 2017;20(8):1074–1082. doi: 10.1016/j.jval.2017.04.017
   PubMed Web of Science ®Google Scholar
• Henrard S, Devleesschauwer B, Beutels P, et al. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis. 2014;9(1):39–47. doi: 10.1186/1750-1172-9-39
   PubMedGoogle Scholar
• O’Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106–113. doi: 10.1186/s13023-017-0660-y
   PubMed Web of Science ®Google Scholar
• Kessler C, Oldenburg J, Ettingshausen CE, et al. Spotlight on the human factor: building a foundation for the future of haemophilia A management. Haemophilia. 2015;21(2):1–12. doi: 10.1111/hae.12582
   PubMedGoogle Scholar
• Gharibnaseri Z, Davari M, Cheraghali A, et al. Health care resource utilization and cost of care for haemophilia A and B patients in Iran. Transfus Apher Sci. 2016;54(1):122–126. doi: 10.1016/j.transci.2016.01.025
   PubMed Web of Science ®Google Scholar
• Golestani M, Eshghi P, Cheraghali A. Cost components of treatment protocols of haemophilia patients with inhibitors using bypassing agents in Iran. Iran J Pharm Sci. 2016;12(2):85–90.
   Google Scholar
• Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost. 2011;37(7):737–744. doi: 10.1055/s-0031-1297164
   PubMed Web of Science ®Google Scholar
• Majid Z, Tahir F, Qadar LT, et al. Hemophilia a with a rare presentation of hemarthrosis and arthropathy involving multiple joints in a young male child. Cureus. 2019;11(4):e4524.
   PubMed Web of Science ®Google Scholar
• Nerich V, Tissot E, Faradji A, et al. Cost of illness study of severe haemophilia A and B in five French haemophilia treatment centres. Pharm World Sci. 2008;30(3):287–292. doi: 10.1007/s11096-007-9181-4
   PubMedGoogle Scholar
• Exchange rate. [cited 10 Jun 2018]. Available from: http://www.cbi.ir.
   Google Scholar
• Wonderling D. Introduction to health economics. 2nd ed. Berkshire: McGra Hill Education; 2011.
   Google Scholar
• Van Houtven CH, Ramsey SD, Hornbrook MC, et al. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist. 2010;15(8):883–893. doi: 10.1634/theoncologist.2010-0005
   PubMed Web of Science ®Google Scholar
• Details of workers’ wages in 2016. [cited 2018 Apr 10]. Available from: https://www.mcls.gov.ir
   Google Scholar
• Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• xx. The number of hemophilia patients in Iran. Tehran: Iranian Hemophilia Society; [cited 2018 Feb 14]. Available from: http://irchcc.ir
   Google Scholar
• Koeberlein-Neu J, Runkel B, Hilberg T. Cost utility of a six-month programmed sports therapy in patients with haemophilia. Haemophilia. 2018;24(3):385–394. doi: 10.1111/hae.13459
   PubMed Web of Science ®Google Scholar
• Khosravi B, Soltani S, Javan-Noughabi J, et al. Health care expenditure in the Islamic Republic of Iran versus other high spending countries. Iran J Med Sci. 2017;31(1):71–80.
   Google Scholar
• Keshavarz K, Kebriaeezadeh A, Alavian SM, et al. Economic burden of hepatitis B virus-related diseases: Evidence from Iran. Hepat Monthly. 2015;15(4):254–263.
   Web of Science ®Google Scholar
• Cavazza M, Kodra Y, Armeni P, et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(1):53–65. doi: 10.1007/s10198-016-0785-2
   PubMed Web of Science ®Google Scholar
• Minno GD, Capua MD, Cerbone A, et al. Cost of care of haemophilia with inhibitors. Haemophilia. 2010;16(1):e190–e201. doi: 10.1111/j.1365-2516.2009.02100.x
   PubMed Web of Science ®Google Scholar
• Bazyar M, Akbari F, Mahmoudi M. Medical and non-medical direct costs of cancers in patients hospitalized in Imam Khomeini cancer institution-2010. J Hosp. 2012;11(1):39–50.
   Google Scholar
• Longo C, Bereza B. A comparative analysis of monthly out-of-pocket costs for patients with breast cancer as compared with other common cancers in Ontario, Canada. Curr Oncol. 2011;18(1):1–18. doi: 10.3747/co.v18i1.681
   PubMed Web of Science ®Google Scholar
• Chen S-L. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5):126–133.
   PubMed Web of Science ®Google Scholar
• Jadhav U, Mukherjee K. Assessment of healthcare measures, healthcare resource use, and cost of care among severe hemophilia A patients in Mumbai region of India. J Postgrad Med. 2018;64(3):138–146. doi: 10.4103/jpgm.JPGM_701_16
   PubMed Web of Science ®Google Scholar